428 completed, 126 recruiting, 119 terminated, 116 unknown. 604 Phase 2, 346 Phase 1, 99 Phase 3, 21 Early Phase 1, 18 Not applicable.
Follow Temozolomide: new trials by email Literature Review of Temozolomide trials Research Report on Temozolomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 60 | 2026-12-15 | 2026-10-20 |
| PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging - Glioblastoma | Phase 3 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 60 | 2026-12-01 | 2026-07-07 |
| Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ) - Newly Diagnosed Glioblastoma, IDH-wildtype | Phase 2 / Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 60 | 2026-10-15 | 2026-10-14 |
| Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer NLG802 (indoximod Prodrug), Temozolomide - Progressive Pediatric Brain Cancer | Phase 1 | Not yet recruiting | Lumos Pharma | 30 | 2026-10-08 | 2026-07-28 |
| Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy - Glioblastoma | Phase 2 | Not yet recruiting | Wei Jiang | 94 | 2026-10-01 | 2026-08-27 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-09-30 | 2026-09-11 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma Levetiracetam Extended-Release Granules, Temozolomide (TMZ), Radiotherapy - Glioblastoma | Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 140 | 2026-09-01 | 2026-08-11 |
| Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma Archive Sample Retrieval, Biospecimen Collection, Chest Radiography - Glioblastoma, IDH-Wildtype | Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-08-28 | 2026-10-15 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation Lenvatinib, TMZ (Temozolomide), radiotherapy - Glioma, Glioblastoma (GBM) | Phase 2 | Not yet recruiting | Dongguan People's Hospital | 138 | 2026-08-10 | 2026-08-10 |
| Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer Toripalimab; Etoposide - SCLC, Extensive Stage, Bayesian | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 130 | 2026-08-01 | 2026-07-13 |
Showing 20 of 939. Sign in to see all of them.
Glioblastoma (415) · Brain Neoplasms (165) · Glioma (164) · Gliosarcoma (132) · Astrocytoma (116) · Central Nervous System Neoplasms (110) · Melanoma (76) · Oligodendroglioma (74) · Neuroblastoma (44) · Medulloblastoma (33) · Neoplasms (33) · Recurrence (32) · Neoplasm Metastasis (29) · Ependymoma (26) · Sarcoma (24)
National Cancer Institute (NCI) (60) · M.D. Anderson Cancer Center (30) · Memorial Sloan Kettering Cancer Center (25) · Duke University (24) · Merck Sharp & Dohme LLC (22) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (19) · European Organisation for Research and Treatment of Cancer - EORTC (17) · Children's Oncology Group (12) · Mayo Clinic (12) · University of California, San Francisco (12) · Northwestern University (11) · Jonsson Comprehensive Cancer Center (10) · Alliance for Clinical Trials in Oncology (9) · Dana-Farber Cancer Institute (9) · Gustave Roussy, Cancer Campus, Grand Paris (9)
United States (588) · China (100) · France (89) · Canada (77) · Germany (70) · Italy (70) · United Kingdom (66) · Spain (59) · Australia (54) · Netherlands (48) · Switzerland (47) · Belgium (35) · Austria (32) · Denmark (24) · Israel (23)
David A. Reardon, MD (8) · Henry S. Friedman, MD (8) · Annick Desjardins, MD, FRCPC (5) · Jeffrey Raizer, MD (4) · Maryam Fouladi, MD (4) · Roger Stupp, MD (4) · Svetomir Markovic, MD, PhD (4) · Annick Desjardins, MD (3)
PMID 36346112, PMID 29982805, PMID 32691060, PMID 16200343, PMID 17705175, PMID 23243055, PMID 24309981, PMID 24344045, PMID 24552317, PMID 25113840, PMID 28039367, PMID 29077941, PMID 29412784, PMID 33842889, PMID 36188432, PMID 38197800, PMID 39571596, PMID 11772431, PMID 12039921, PMID 12649108, PMID 12675312, PMID 12763216, PMID 12829671, PMID 12947072, PMID 13680158, PMID 14769138, PMID 15073861, PMID 15173079, PMID 15234047, PMID 15251162, PMID 15565574, PMID 15758009, PMID 15758010, PMID 16192602, PMID 16203762, PMID 16234526, PMID 16260693, PMID 16321761, PMID 16520474, PMID 16530701, PMID 16735709, PMID 16786120, PMID 16899365, PMID 16982773, PMID 17031561, PMID 17114659, PMID 17134114, PMID 17252015, PMID 17609661, PMID 17664336
2023 (10), 2018 (8), U10CA180868 (8), U10CA180886 (8), 2008 (6), 2009 (6), P30CA008748 (6), P30CA060553 (6), U10CA180821 (6), 2017 (5), 2019 (5), 2025 (5), P30CA043703 (5), U01CA062475 (5), U10CA021661 (5)